US Pharma MarketingThe post Gilead and MSD’s once-weekly HIV pill meets primary endpoints in Phase III trials appeared first on Clinical Trials Arena.
Gilead and MSD’s once-weekly HIV pill meets primary endpoints in Phase III trials
Gilead and MSD will be filing the data from the Phase III trials of the once-weekly HIV pill to regulatory authorities. Gilead and MSD will be filing the data from the Phase III trials of the once-weekly HIV pill to regulatory authorities. Gilead and MSD have been developing the once-weekly oral medications for HIV together. Credit: Tatyana Frolova / Shutterstock.com Gilead Sciences and MSD’s human immunodeficiency virus (HIV) once weekly tablet combination has met primary endpoints in two Phase III trials. In the 48-week ISLEND-1 (NCT06630286) and ISLEND-2 (NCT06630299) trials, the two pharmaceutical companies investigated the single-tablet HIV treatment regimen…
Gilead and MSD will be filing the data from the Phase III trials of the once-weekly HIV pill to regulatory authorities.
Source: Clinical Trials Arena